Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

529 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Investigation of six testicular germ cell tumor susceptibility genes suggests a parent-of-origin effect in SPRY4.
Karlsson R, Andreassen KE, Kristiansen W, Aschim EL, Bremnes RM, Dahl O, Fosså SD, Klepp O, Langberg CW, Solberg A, Tretli S, Magnusson PK, Adami HO, Haugen TB, Grotmol T, Wiklund F. Karlsson R, et al. Among authors: dahl o. Hum Mol Genet. 2013 Aug 15;22(16):3373-80. doi: 10.1093/hmg/ddt188. Epub 2013 May 2. Hum Mol Genet. 2013. PMID: 23640991
Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group.
Olofsson SE, Tandstad T, Jerkeman M, Dahl O, Ståhl O, Klepp O, Bremnes RM, Cohn-Cedermark G, Langberg CW, Laurell A, Solberg A, Stierner U, Wahlqvist R, Wijkström H, Anderson H, Cavallin-Ståhl E. Olofsson SE, et al. Among authors: dahl o. J Clin Oncol. 2011 May 20;29(15):2032-9. doi: 10.1200/JCO.2010.29.1278. Epub 2011 Apr 11. J Clin Oncol. 2011. PMID: 21482994 Clinical Trial.
Gene variations in sex hormone pathways and the risk of testicular germ cell tumour: a case-parent triad study in a Norwegian-Swedish population.
Kristiansen W, Andreassen KE, Karlsson R, Aschim EL, Bremnes RM, Dahl O, Fosså SD, Klepp O, Langberg CW, Solberg A, Tretli S, Adami HO, Wiklund F, Grotmol T, Haugen TB. Kristiansen W, et al. Among authors: dahl o. Hum Reprod. 2012 May;27(5):1525-35. doi: 10.1093/humrep/des075. Epub 2012 Mar 8. Hum Reprod. 2012. PMID: 22402210
Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study.
Myklebust MP, Thor A, Rosenlund B, Gjengstø P, Karlsdottir Á, Brydøy M, Bercea BS, Olsen C, Johnson I, Berg MI, Langberg CW, Andreassen KE, Kjellman A, Haugnes HS, Dahl O. Myklebust MP, et al. Among authors: dahl o. Sci Rep. 2021 Aug 2;11(1):15582. doi: 10.1038/s41598-021-94812-2. Sci Rep. 2021. PMID: 34341387 Free PMC article.
Long-term follow-up after risk-adapted treatment in clinical stage 1 (CS1) nonseminomatous germ-cell testicular cancer (NSGCT) implementing adjuvant CVB chemotherapy. A SWENOTECA study.
Tandstad T, Cohn-Cedermark G, Dahl O, Stierner U, Cavallin-Stahl E, Bremnes RM, Klepp O. Tandstad T, et al. Among authors: dahl o. Ann Oncol. 2010 Sep;21(9):1858-1863. doi: 10.1093/annonc/mdq026. Epub 2010 Feb 8. Ann Oncol. 2010. PMID: 20142410 Free article. Clinical Trial.
Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group.
Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, Laurell A, Stierner UK, Ståhl O, Cavallin-Ståhl EK, Klepp OH, Dahl O, Cohn-Cedermark G. Tandstad T, et al. Among authors: dahl o. J Clin Oncol. 2011 Feb 20;29(6):719-25. doi: 10.1200/JCO.2010.30.1044. Epub 2011 Jan 4. J Clin Oncol. 2011. PMID: 21205748
529 results